Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma Journal Article
| Authors: | Forlenza, C. J.; Rosenzweig, J.; Mauguen, A.; Buhtoiarov, I.; Cuglievan, B.; Dave, H.; Deyell, R. J.; Flerlage, J. E.; Franklin, A. K.; Krajewski, J.; Leger, K. J.; Marks, L. J.; Norris, R. E.; Pacheco, M.; Willen, F.; Yan, A. P.; Harker-Murray, P. D.; Giulino-Roth, L. |
| Article Title: | Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma |
| Abstract: | Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with similar to 50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free survival (PFS) when used as consolidation after autologous stem cell transplantation (ASCT) in adults with high-risk relapsed/refractory HL. Data on brentuximab vedotin as consolidative therapy after ASCT in pediatric patients with HL are extremely limited, with data of only 11 patients reported in the literature. We performed a retrospective analysis of 67 pediatric patients who received brentuximab vedotin as consolidation therapy after ASCT for the treatment of relapsed/refractory HL to describe the experience of this regimen in the pediatric population. This is the largest cohort reported to date. We found that brentuximab vedotin was well tolerated with a safety profile similar to that of adult patients. With a median follow-up of 37 months, the 3-year PFS was 85%. These data suggest a potential role for the use of brentuximab vedotin as consolidation therapy after ASCT for children with relapsed/refractory HL. |
| Keywords: | salvage therapy; chemotherapy; risk; children; stem-cell transplantation; disease; recurrent; multicenter; high-dose therapy; adolescents |
| Journal Title: | Blood Advances |
| Volume: | 7 |
| Issue: | 13 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-07-11 |
| Start Page: | 3225 |
| End Page: | 3231 |
| Language: | English |
| ACCESSION: | WOS:001039259700001 |
| DOI: | 10.1182/bloodadvances.2022009323 |
| PROVIDER: | wos |
| PMCID: | PMC10338202 |
| PUBMED: | 36897253 |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF -- Corresponding authors are MSK authors: Jaclyn Rosenzweig and Christopher J. Forlenza -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work